Search results for PX-TA1040

Efalizumab Biosimilar – Anti-ITGAL, CD11a mAb – Research Grade, ProteoGenix, PX-TA1040

Description of Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb - Research Grade General information on Anti-ITGAL/CD11a(Homo sapiens) (Efalizumab) Monoclonal Antibody Efalizumab is a recombinant monoclonal antibody to Human CD11A. Under the trade name Raptiva, it is a drug that was previously used to treat autoimmune diseases and was originally used to treat psoriasis. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and inhibits lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab has been associated with fatal brain infections.